- Home
- BCDA vs SVRE Comparison
BCDA vs SVRE Comparison
Compare BCDA & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SVRE
- Stock Information
- Founded
- BCDA N/A
- SVRE 2014
- Country
- BCDA United States
- SVRE Israel
- Employees
- BCDA N/A
- SVRE N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SVRE
- Sector
- BCDA Health Care
- SVRE
- Exchange
- BCDA Nasdaq
- SVRE Nasdaq
- Market Cap
- BCDA 7.9M
- SVRE 2.6M
- IPO Year
- BCDA N/A
- SVRE 2022
- Fundamental
- Price
- BCDA $2.68
- SVRE $0.12
- Analyst Decision
- BCDA Strong Buy
- SVRE
- Analyst Count
- BCDA 1
- SVRE 0
- Target Price
- BCDA $25.00
- SVRE N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- SVRE 5.3M
- Earning Date
- BCDA 11-06-2024
- SVRE 08-27-2024
- Dividend Yield
- BCDA N/A
- SVRE N/A
- EPS Growth
- BCDA N/A
- SVRE N/A
- EPS
- BCDA N/A
- SVRE N/A
- Revenue
- BCDA $428,000.00
- SVRE $458,952.00
- Revenue This Year
- BCDA $6.92
- SVRE N/A
- Revenue Next Year
- BCDA N/A
- SVRE $422.52
- P/E Ratio
- BCDA N/A
- SVRE N/A
- Revenue Growth
- BCDA 0.71
- SVRE N/A
- 52 Week Low
- BCDA $1.96
- SVRE $0.11
- 52 Week High
- BCDA $23.25
- SVRE $1.50
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- SVRE 29.85
- Support Level
- BCDA $2.39
- SVRE $0.12
- Resistance Level
- BCDA $2.90
- SVRE $0.13
- Average True Range (ATR)
- BCDA 0.18
- SVRE 0.01
- MACD
- BCDA -0.00
- SVRE 0.00
- Stochastic Oscillator
- BCDA 53.70
- SVRE 24.66
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.